FDA Approves Two Suppliers for Critical Cancer Drugs

The FDA announced yesterday that it has approved two new suppliers for two critical cancer drugs that have experienced shortages, according to a Newsday report.

The FDA will temporarily allow a replacement drug for Doxil, a drug for ovarian and other cancers, to be imported. The drug has not been available to new patients for months. The FDA also approved a supplier for a preservative-free version of methotrexate, which is used to treat children with acute lymphoblastic leukemia and bone cancer.

Related Articles on Supply Chain:
Cardinal Health to Start Offering its Complete Portfolio of Surgical Gloves in Sustainable, Half-Fold Packaging
Teleflex Signs Agreement With HealthTrust for Arrow Intra-Aortic Balloon Pumps and Catheters

SourceMedical Launches Vision OnDemand Clinical and Business Management System for ASCs

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like

 

Featured Whitepapers

Featured Webinars